SCHEMBL2555267

SCHEMBL2555267

O=C(O)CC1(CBr)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9681942 0.83 ALDH1A1 (0.54)
SCHEMBL2689421 0.80 CYP1A2 (0.43)
SCHEMBL5713265 0.77
SCHEMBL1659398 0.76
SCHEMBL28945842 0.75 LMNA (0.36)
SCHEMBL25293741 0.74
SCHEMBL12203096 0.74
SCHEMBL625309 0.74
SCHEMBL2612028 0.74
SCHEMBL5265368 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3409658-B9 TETRAHYDRONAPHTHALENE DERIVATIVE ONO PHARMACEUTICAL CO (JP) 2024-07-17 EP disclosed
EP-3409658-B1 TETRAHYDRONAPHTHALENE DERIVATIVE ONO PHARMACEUTICAL CO (JP) 2024-03-06 EP disclosed
CN-115667243-A Tetrahydroisoquinoline compounds as NRF2 activators 希四克斯探索有限公司 2023-01-31 CN disclosed
WO-2021074279-A1 SPIRO-FUSED TRICYCLIC MAP4K1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2021-04-22 WO disclosed
US-10730830-B2 Tetrahydronaphthalene derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2020-08-04 US disclosed
US-20190031605-A1 TETRAHYDRONAPHTHALENE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2019-01-31 US disclosed
EP-3409658-A1 TETRAHYDRONAPHTHALENE DERIVATIVE ONO Pharmaceutical Co., Ltd. (JP) 2018-12-05 EP disclosed
EP-2552892-A1 EFFICIENT SYNTHESIS FOR THE PREPARATION OF MONTELUKAST AND NOVEL CRYSTALLINE FORM OF INTERMEDIATES THEREIN KRKA, D.D., Novo Mesto (SI) 2013-02-06 EP disclosed
WO-2011121091-A1 EFFICIENT SYNTHESIS FOR THE PREPARATION OF MONTELUKAST AND NOVEL CRYSTALLINE FORM OF INTERMEDIATES THEREIN KRKA, D.D., NOVO MESTO (SI) 2011-10-06 WO disclosed
WO-2008098965-A1 PROCESS FOR OBTAINING MONTELUKAST INKE, S.A. (ES) 2008-08-21 WO disclosed
EP-1958936-A1 Process for obtaining montelukast INKE, S.A. (ES) 2008-08-20 EP disclosed
US-20080194825-A1 PROCESS FOR OBTAINING MONTELUKAST INKE, S.A. (ES) 2008-08-14 US disclosed
CN-1420113-A Method for preparing Menglusitena and intermediate preparation thereof SHANGDI XINSHIJI BIO MEDICAL I (CN) 2003-05-28 CN disclosed